IMMUNOHISTOCHEMICAL ANALYSIS OF BREAST CANCER SUBTYPES AND THEIR CORRELATION WITH Ki 67 INDEX
AbstractBackground: Breast cancer is the second most common cancer in females including Pakistan. Nowadays immunohistochemistry has revolutionized management of breast cancer. In this study, we determined the frequency of various subtypes of breast cancer on the basis of immunohistochemical staining and their correlation with ki 67 index. Methods: Fifty consecutive diagnosed breast cancers cases received during the period February 2014 to February 2016, at Ayub Medical College, Pathology Department were included in this cross-sectional study. Immunohistochemistry for Estrogen receptor (ER), Progesterone receptor (PgR), Her2neu and ki 67 index were applied and the results were recorded. Results: Out of 50 cases, 34 (68%) were positive for ER and PgR, 6 (12%) were positive for Her 2neu while 6 (12%) were triple positive and 4 (8%) were triple negative. Conclusion: Low risk Luminal A was the most frequently encountered breast cancer category.Keywords: ER, PgR, Her 2 neu; Triple positive breast cancer; Triple negative breast cancer
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, Maclntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1(4):505–27.
Formenti SC, Arsian AA, Love SM. Global breast cancer: The lessons to bring home. Int J Breast Cancer 2012;2012:249501.
Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011;121(10):3786–8.
Turaga K, Acs G, Laronga C. Gene expression profiling in breast cancer. Cancer Control 2010;17(3):177–82.
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109(1):123–39.
Piccart-Gebhart MJ. New Developments in Hormone Receptor–Positive Disease. Oncologist 2010;15(Suppl 5):18–28.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-Positive breast cancer. N Engl J Med 2011;365(14):1273–83.
Bangal VB, Shinde KK, Gavhane SP, Singh RK. Breast Carcinoma in women-A rising threat. Int J Biomed Adv Res 2013;4(2):73–6.
Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010;23(Suppl 2):S560–4.
Ahmed R, Ud Din H, Akhtar F, Afzal S, Muhammad I, Hashmi SN. Immunohistochemical expression of epidermal growth factot receptor and C-KIT in triple negative breast cancer. J Coll Physicians Surg Pak 2016;26(7):570–2.
Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumour characteristics among U.S women. Breast Cancer Res 2007;9(3):R28.
Lee SK, Bae SY, Lee JH, Lee HC, Yi H, Kil WH, et al. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS One 2015;10(8):e0124658.
Wang J, Sang D, Xu B, Yuan P, Ma F, Lu Y, et al. Value of breast cancer Molecular Subtypes and Ki 67 expression in the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. Medicine (Baltimore) 2016;95(18):e3518.
Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, et al. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights Oncol 2014;8:107–11.
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, Azambuja E, et al. Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. J Clin Oncol 2014;32(25):2794–803.
Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 2011(11):292.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER 1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200(3):290–7.
Shokouh TZ, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study. Medicine (Baltimore) 2015;94(32):e1359.
Badowska-Kozakiewicz AM, Budzik MP. Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn) 2016;20(6):436–43.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109(1):25–32.
Alluri P, Newman L. Basal-like and Triple Negative Breast Cancers: Searching For Positives Among Many Negatives. Surg Oncol Clin N Am 2014;23(3):567–77.